Tunicamycin inhibits diabetes.

Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology

PubMedID: 22508066

Shaabani N, Honke N, Lang PA, Görg B, Proksch P, Gailus N, Gotoh T, Häussinger D, Lang KS. Tunicamycin inhibits diabetes. Cell Physiol Biochem. 2012;29(3-4):595-602.
BACKGROUND
Autoimmune diseases are characterized by a breakdown of immunologic tolerance, and this breakdown can lead to life-threatening or lifelong disorders. Moreover; drugs that are used to treat these diseases are few in number and are associated with many serious adverse effects.

METHODS
We used the rat insulin promoter-glycoprotein mouse model to analyze the role of tunicamycin in the process of autoimmune diabetes; the P14 mouse model to analyze the effect of tunicamycin on CD8(+) T cells; chop knockout mice to analyze the role of tunicamycin on an endoplasmic reticulum stress model; and fluorescence-activated cell sorting, quantitative real-time polymerase chain reaction, and histologic methods.

RESULTS
We found that a single dose of tunicamycin reduced the activation and pancreatic infiltration of CD8(+) T cells. This activity delayed the incidence of virus-induced diabetes and improved survival rates.

CONCLUSION
Tunicamycin may offer therapeutic opportunities for T cell-mediated autoimmune diseases such as diabetes.